Part 3.7 / M18
3. TEIL 3: TABELLE ZUR HARMONISIERTEN EINSTUFUNG UND KENNZEICHNUNG
|
Index-Nr. |
►M18 Chemische Bezeichnung ◄ |
EG-Nr. |
CAS-Nr. |
Einstufung |
Kennzeichnung |
►M18 Spezifische Konzentrationsgrenzen, M-Faktoren und ATE (*1) ◄ |
Anmerkungen |
|||
|
Kodierung der Gefahrenhinweise |
Piktogramm, Kodierung der Signalworte |
Kodierung der Gefahrenhinweise |
Kodierung der ergänzenden Gefahrenmerkmale |
|||||||
|
006-044-00-7 |
Isoproturon (ISO); 3-(4-Isopropylphenyl)-1,1-dimethylharnstoff |
251-835-4 |
Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H373 (Blut) H400 H410 |
GHS08 GHS09 Wng |
H351 H373 (Blut) H410 |
|
M = 10 M = 10 |
|
|
|
015-101-00-5 |
Phosmet (ISO); S-[(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl] O,O-Dimethyldithiophosphat; O,O-Dimethyl-S-phthalimidomethyldithiophosphat |
211-987-4 |
Repr. 2 Acute Tox. 4 Acute Tox. 3 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361f H332 H301 H370 (Nervensystem) H400 H410 |
GHS08 GHS06 GHS09 Dgr |
H361f H332 H301 H370 (Nervensystem) H410 |
|
M = 100 M = 100 |
|
|
|
016-096-00-2 |
Thifensulfuron-methyl (ISO); Methyl-3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophen-2-carboxylat |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 100 M = 100 |
|
|
|
017-011-00-1 |
Natriumhypochloritlösung … % Cl aktiv |
231-668-3 |
Skin Corr. 1B Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H314 H318 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
EUH031 |
M = 10 M = 1 EUH031: C ≥ 5 % |
B |
|
|
025-002-00-9 |
Kaliumpermanganat |
231-760-3 |
Ox. Sol. 2 Repr. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H272 H361d H302 H400 H410 |
GHS03 GHS08 GHS07 GHS09 Dgr |
H272 H361d H302 H410 |
|
|
|
|
|
603-180-00-4 |
Colecalciferol; Cholecalciferol; Vitamin D3 |
200-673-2 |
Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 STOT RE 1 |
H330 H310 H300 H372 |
GHS06 GHS08 Dgr |
H330 H310 H300 H372 |
|
Einatmung: ATE = 0,05 mg/L (Stäube oder Nebel) Dermal: ATE = 50 mg/kg KG Oral: ATE = 35 mg/kg KG STOT RE 1; H372: C ≥ 3 % STOT RE 2; H373: 0,3 % ≤ C < 3 % |
|
|
|
604-014-00-3 |
Chlorkresol; 4-Chlor-m-kresol; 4-Chlor-3-methylphenol |
200-431-6 |
Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 STOT SE 3 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 3 |
H302 H314 H318 H335 H317 H400 H412 |
GHS07 GHS05 GHS09 Dgr |
H302 H314 H335 H317 H410 |
|
M = 1 |
|
|
|
604-016-00-4 |
1,2-Dihydroxybenzol; Brenzcatechin |
204-427-5 |
Carc. 1Β Muta. 2 Acute Tox. 3 Acute Tox. 3 Skin Irrit. 2 Eye Irrit. 2 |
H350 H341 H311 H301 H315 H319 |
GHS08 GHS06 Dgr |
H350 H341 H311 H301 H315 H319 |
|
Oral: ATE = 300 mg/kg KG Dermal: ATE = 600 mg/kg KG |
|
|
|
604-090-00-8 |
4-tert-Butylphenol |
202-679-0 |
Repr. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 1 |
H361f H315 H318 H410 |
GHS08 GHS05 GHS09 Dgr |
H361f H315 H318 H410 |
|
M = 1 |
|
|
|
604-094-00-X |
Isoeugenol; [1] (E)-2-Methoxy-4-(prop-1-enyl)phenol; [2] (Z)-2-Methoxy-4-(prop-1-enyl)phenol [3] |
202-590-7 [1] 227-678-2 [2] 227-633-7 [3] |
97-54-1 [1] 5932-68-3 [2] 5912-86-7 [3] |
Skin Sens. 1A |
H317 |
GHS07 Wng |
H317 |
|
Skin Sens. 1A; H317: C ≥ 0,01 % |
|
|
605-003-00-6 |
Acetaldehyd; Ethanal |
200-836-8 |
Flam. Liq. 1 Carc. 1B Muta. 2 STOT SE 3 Eye Irrit. 2 |
H224 H350 H341 H335 H319 |
GHS02 GHS08 GHS07 Dgr |
H224 H350 H341 H335 H319 |
|
|
|
|
|
607-096-00-9 |
Maleinsäureanhydrid |
203-571-6 |
Acute Tox. 4 STOT RE 1 Skin Corr. 1B Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1A |
H302 H372 (Atmungsorgane) (Einatmung) H314 H318 H334 H317 |
GHS07 GHS08 GHS05 Dgr |
H302 H372 (Atmungsorgane) (Einatmung) H314 H334 H317 |
EUH071 |
Skin Sens. 1A; H317: C ≥ 0,001 % |
|
|
|
607-103-00-5 |
Bernsteinsäureanhydrid |
203-570-0 |
Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H302 H314 H318 H334 H317 |
GHS07 GHS05 GHS08 Dgr |
H302 H314 H334 H317 |
EUH071 |
|
|
|
|
607-113-00-X |
Isobutylmethacrylat |
202-613-0 |
Flam. Liq. 3 STOT SE 3 Skin Irrit. 2 Skin Sens. 1B |
H226 H335 H315 H317 |
GHS02 GHS07 Wng |
H226 H335 H315 H317 |
|
|
D |
|
|
607-373-00-4 |
Quizalofop-P-tefuryl (ISO); (+/–)-Tetrahydrofurfuryl-(R)-2-[4-(6-chlorchinoxalin-2-yloxy)phenyloxy]propionat |
414-200-4 |
Carc. 2 Repr. 2 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H361fd H302 H373 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H361fd H302 H373 H410 |
|
M = 1 M = 1 |
|
|
|
607-724-00-1 |
2,3,5,6-Tetrafluor-4-(methoxymethyl)benzyl (1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-en-1-yl]cyclopropancarboxylat; Epsilon-metofluthrin |
— |
Acute Tox. 4 Acute Tox. 3 STOT SE 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H332 H301 H370 (Nervensystem) H373 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H332 H301 H370 (Nervensystem) H373 H410 |
|
M = 100 M = 100 |
|
|
|
607-725-00-7 |
Isopropyl (2E,4E,7S)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoat; S-Methopren |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 1 M = 1 |
|
|
|
607-726-00-2 |
Pinoxaden (ISO); 8-(2,6-Diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7H-pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoat |
— |
Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 STOT SE 3 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 3 |
H361d H332 H302 H319 H335 H317 H400 H412 |
GHS08 GHS07 GHS09 Wng |
H361d H332 H302 H319 H335 H317 H410 |
|
Einatmung: ATE = 4,63 mg/L (Stäube oder Nebel) Oral: ATE = 500 mg/kg KG M = 1 |
|
|
|
607-727-00-8 |
Tetramethrin (ISO); (1,3-Dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropancarboxylat |
231-711-6 |
Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H371 (Nervensystem) (Einatmung) H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H371 (Nervensystem) (Einatmung) H410 |
|
M = 100 M = 100 |
|
|
|
607-728-00-3 |
(1,3,4,5,6,7-Hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropancarboxylat |
214-619-0 |
Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H371 (Nervensystem) (Einatmung) H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H371 (Nervensystem) (Einatmung) H410 |
|
M = 100 M = 100 |
|
|
|
607-729-00-9 |
Mesosulfuron-methyl (ISO); Methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methansulfonamido)-p-toluat; |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 100 M = 100 |
|
|
|
607-730-00-4 |
Spirodiclofen (ISO); 3-(2,4-Dichlorphenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrat |
— |
Carc. 1B Repr. 2 STOT RE 2 Skin Sens. 1B Aquatic Chronic 1 |
H350 H361f H373 H317 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H361f H373 H317 H410 |
|
M = 10 |
|
|
|
607-731-00-X |
Natriummethyl[(4-aminophenyl)sulfonyl]carbamat: Natriummethyl (EZ)-sulfanilylcarbonimidat; Asulam-Natrium |
218-953-8 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
M = 1 M = 1 |
|
|
|
607-732-00-5 |
Salicylsäure |
200-712-3 |
Repr. 2 Acute Tox. 4 Eye Dam. 1 |
H361d H302 H318 |
GHS08 GHS07 GHS05 Dgr |
H361d H302 H318 |
|
|
|
|
|
608-068-00-9 |
Flutianil (ISO); (2Z)-{[2-Fluor-5-(trifluormethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-yliden]acetonitril |
— |
Aquatic Chronic 1 |
H410 |
GHS09 Wng |
H410 |
|
M = 100 |
|
|
|
612-293-00-8 |
Reaktionsmasse aus 1-[2-(2-Aminobutoxy)ethoxy]but-2-ylamin und 1-({[2-(2-Aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamin |
447-920-2 |
— |
Repr. 2 Acute Tox. 4 Skin Corr. 1B Eye Dam. 1 |
H361f H302 H314 H318 |
GHS08 GHS07 GHS05 Dgr |
H361f H302 H314 |
EUH071 |
|
|
|
613-167-00-5 |
Reaktionsmasse aus 5-Chlor-2-methyl-2H-isothiazol-3-on und 2-Methyl-2H-isothiazol-3-on (3:1) |
— |
Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H301 H314 H318 H317 H400 H410 |
GHS06 GHS05 GHS09 Dgr |
H330 H310 H301 H314 H317 H410 |
EUH071 |
Skin Corr. 1C; H314: C ≥ 0,6 % Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 % Eye Dam. 1; H318: C ≥ 0,6 % Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100 |
B |
|
|
613-205-00-0 |
Propiconazol (ISO); (2RS,4RS;2RS,4SR)-1-{[2-(2,4-Dichlorphenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazol |
262-104-4 |
Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360D H302 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H360D H302 H317 H410 |
|
M = 1 M = 1 |
|
|
|
613-326-00-9 |
2-Methyl-2H-isothiazol-3-on |
220-239-6 |
Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H330 H311 H301 H314 H318 H317 H400 H410 |
GHS05 GHS06 GHS09 Dgr |
H330 H311 H301 H314 H317 H410 |
EUH071 |
Skin Sens. 1A; H317: C ≥ 0,0015 % M = 10 M = 1 |
|
|
|
613-327-00-4 |
Pyroxsulam (ISO); N-(5,7-Dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluormethyl)pyridin-3-sulfonamid |
— |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
M = 100 M = 100 |
|
|
|
613-328-00-X |
1-Vinylimidazol |
214-012-0 |
Repr. 1B |
H360D |
GHS08 Dgr |
H360D |
|
Repr. 1B; H360D: C ≥ 0,03 % |
|
|
|
614-001-00-4 |
Nikotin (ISO); 3-[(2S)-1-Methylpyrrolidin-2-yl]pyridin |
200-193-3 |
Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 Aquatic Chronic 2 |
H330 H310 H300 H411 |
GHS06 GHS09 Dgr |
H330 H310 H300 H411 |
|
Einatmung: ATE = 0,19 mg/L (Stäube oder Nebel) Dermal: ATE = 70 mg/kg KG Oral: ATE = 5 mg/kg KG |
|
|
|
616-224-00-2 |
Amisulbrom (ISO); 3-(3-Brom-6-fluor-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazol-1-sulfonamid |
— |
Carc. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H319 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H319 H410 |
|
M = 10 M = 10 |
|
|